N677 Controlled Substance Exam 2026/2027 – 20+ Questions & Answers | DEA Schedules, Opioids, Pain Management & NP Prescribing

This comprehensive N677 Controlled Substance Exam 2026/2027 study resource contains 20+ exam questions with detailed answers across 13 pages, focusing on controlled-substance pharmacology, DEA drug schedules, opioid analgesics, pain management, benzodiazepines, NSAIDs, acetaminophen, local anesthetics and nurse practitioner prescribing responsibilities. The material combines direct questions, drug-classification exercises, clinical safety considerations and advanced-practice prescribing concepts. It is particularly useful for N677 students who need to distinguish controlled-substance schedules, recognize opioid adverse effects and withdrawal, evaluate analgesic risks and review professional prescribing requirements. A central examination topic is the DEA controlled-substance scheduling system. Students review the relative abuse potential of Schedules I through V and classify commonly encountered medications and substances, including methylphenidate, diazepam, fentanyl, morphine, hydrocodone combinations, testosterone, phentermine, alprazolam, carisoprodol, zolpidem, amphetamine/dextroamphetamine and methadone. The document also tests recognition of Schedule I substances and examines the scheduling of prescription opioids, stimulants, benzodiazepines and certain cough preparations. The guide provides substantial coverage of opioid pharmacology and pain management. Students review common opioid adverse effects such as respiratory depression, constipation, drowsiness, nausea, vomiting, miosis, confusion and pruritus, alongside additional effects associated with pure opioid agonists. Oxycodone and extended-release OxyContin receive focused attention, including their Schedule II classification, prolonged-release characteristics, CNS effects and abuse-deterrent formulation concepts. Codeine metabolism is also discussed, including its conversion to morphine and the clinical importance of CYP2D6 ultrarapid metabolism. Another high-yield section covers opioid withdrawal and dependence-related pharmacology. The document identifies manifestations such as abdominal cramping, diarrhea, nausea, vomiting, lacrimation, rhinorrhea, diaphoresis, piloerection, mydriasis, anxiety, irritability, insomnia, agitation, tremor, yawning and musculoskeletal discomfort. Benzodiazepine pharmacology is addressed through questions concerning tolerance, dependence and the need for gradual discontinuation rather than abrupt cessation. These topics connect controlled-substance pharmacology with the recognition of withdrawal and medication-safety concerns relevant to advanced nursing practice. The resource also reviews multimodal and adjunctive pain pharmacotherapy. Medication classes discussed include serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), skeletal muscle relaxants, COX-2 inhibitors, NSAIDs, acetaminophen, SSRIs, antiepileptic agents and local or regional anesthetics. Lidocaine receives separate attention through questions about local administration and the role of epinephrine. This broad approach helps students differentiate opioid therapy from non-opioid and adjunctive options used in pain management. A clinically important portion concentrates on NSAID and acetaminophen risk assessment. The document identifies factors requiring additional consideration before NSAID use, including hypertension, asthma, concomitant medications, older age, gastrointestinal bleeding risk, renal disease, cardiovascular disease, stroke history, cirrhosis, edema and alcohol intake. Acetaminophen-related questions emphasize liver disease, warfarin use, regular alcohol consumption and concurrent prescription products containing acetaminophen. The material also contrasts medication considerations in renal and hepatic impairment. The exam further addresses advanced-practice prescribing and professional responsibilities. Questions discuss prescribing controlled substances to friends or family, DEA registration, Schedule II–V prescribing, prescription-refill restrictions and historical requirements associated with buprenorphine treatment for opioid use disorder. Because federal controlled-substance rules have changed over time—including removal of the federal DATA-waiver requirement for prescribing buprenorphine for opioid use disorder—the regulatory statements in this 2026 study document should be checked against current federal and state requirements before being used for clinical or legal decision-making. For academic reference, the document itself cites Woo & Robinson, Pharmacotherapeutics for Advanced Practice Nurse Prescribers for several opioid and controlled-substance concepts, including pure opioid agonist effects, codeine metabolism and pediatric safety. This is an appropriate advanced-practice pharmacotherapy reference for N677 students. For current controlled-substance classifications and prescribing regulations, students should additionally consult the U.S. Drug Enforcement Administration (DEA) and current federal and state prescribing guidance, since regulatory requirements may change more rapidly than pharmacology textbooks. Relevant students: This document is primarily relevant to N677 students preparing for the Controlled Substance Exam in 2026/2027. It is especially suitable for nurse practitioner students, APRN students, MSN and DNP students, FNP students, AGNP students, psychiatric-mental health NP students and other graduate nursing students studying advanced pharmacology, pain management and controlled-substance prescribing. The document identifies the course code N677 but does not state a university or college, so no unsupported institution has been added to the title. Keywords: N677 Controlled Substance Exam, N677 exam , N677 questions and answers, N677 study guide, controlled substance exam, controlled substance questions and answers, advanced pharmacology exam, DEA drug schedules, DEA Schedule I II III IV V, Schedule II medications, opioid pharmacology, opioid analgesics, opioid side effects, opioid withdrawal symptoms, pain management pharmacology, controlled substance prescribing, nurse practitioner prescribing, APRN prescribing, DEA registration, oxycodone pharmacology, OxyContin, morphine pharmacology, fentanyl, hydrocodone, codeine metabolism, CYP2D6, methylphenidate, benzodiazepines, alprazolam, diazepam, benzodiazepine dependence, NSAID risk assessment, acetaminophen safety, renal impairment pharmacology, hepatic impairment pharmacology, lidocaine pharmacology, buprenorphine, opioid use disorder, OUD pharmacology, advanced practice nursing pharmacology, FNP pharmacology exam, MSN pharmacology, DNP pharmacology, NP controlled substance exam